Compare iShares MSCI Germany (DAX) (EWG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Germany (DAX) trades at $40.94 (market cap $1.53B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 3.3× iShares MSCI Germany (DAX)'s market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 55 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EWG | TVTX | |
|---|---|---|
Market Cap | $1.53B | $5.02B |
Volume | 1,020,541 | 2,060,842 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $67.52 |
52-Week Low | $38.08 | $26.79 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $41.20 with a modest 0.59% daily gain, though technical indicators signal a bearish trend with moving averages showing 4 buy versus 9 sell signals. The stock faces resistance at $42 with support at $41. Recent European market focus highlights resilience amid ECB rate hikes and energy price pressures affecting regional equities.
Outlook remains cautious due to bearish technicals and macroeconomic headwinds from ECB tightening. Investment opportunity hinges on European economic stability, but risks include prolonged inflation and energy market volatility. Stock-specific fundamentals are unavailable, requiring deeper due diligence.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
